Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Sean M. Healey & AMG Center for ALS is most often covered alongside Massachusetts General Hospital, which appears in 1 of these 1 story. The tracked stories average 2 original sources each.
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Sean M. Healey & AMG Center for ALS is most often covered alongside Massachusetts General Hospital, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Sean M. Healey & AMG Center for ALS appears in 1 tracked Biotech story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sean M. Healey & AMG Center for ALS. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected window for preliminary safety and biomarker data review by the trial committee.
Dosing Initiation
First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.
Trial Selection
NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.
Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
Source: sydneysun.com · malaysiasun.com
Sean M. Healey & AMG Center for ALS is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
